$365,000 cash and 1.51 quarters of funding reported by Papyrus

Second TBS production run clears Papyrus’s internal hurdle

Papyrus Australia Ltd (ASX:PPY) has reported a more encouraging second production-scale board run for TBS Mining Solutions, with internal testing showing significantly improved performance compared with the initial trial. Samples from the run have now been sent to TBS, making external testing and acceptance the next gate before Papyrus can progress towards commercial supply.

The result marks progress on a contract whose timetable was revised after the first trial met specifications on some attributes but identified others requiring further development. The additional run incorporated changes to the product and manufacturing process, following the prior TBS trial extension, which allowed more time for sample production and delivery. TBS testing remains outstanding, and the company says ramp-up milestones are conditional on satisfactory testing and acceptance.

Commercialisation expands beyond one customer

During the September quarter, Papyrus began engaging additional potential customers for its paperboard products. The company described these discussions as an early-stage effort to build a more diversified demand pipeline for its cellulosic fibre technology, while acknowledging that they may not result in commercial agreements.

Its Adelaide Rapid Prototyping and R&D Facility also increased pulp production capacity in August. Papyrus said the expanded capability supports small-scale production for initial commercial requirements while allowing product development and research work to continue. A provisional patent application filed on 21 August covers a method for manufacturing moulded fibre products with fibre reinforcement elements, although potential applications such as UAV airframes have not yet been prototyped, tested or commercially validated.

Loan funding lifts cash, but runway remains tight

Papyrus received $700,000 in loan funding during the quarter, including the $500,000 of unsecured facilities arranged in August. It also drew approximately $148,000 under its existing R&DTI loan facility. The $500,000 loans and the $200,000 Irwin Biotech facility may convert into shares or convertible notes, subject to shareholder approval at the 2026 annual general meeting. The new funding is earmarked for commercialisation, TBS contract delivery and working capital.

The cash-flow numbers leave little room for delay. Papyrus reported net operating cash outflow of $538,000 and net investing outflow of $185,000 for the quarter, partly offset by $843,000 of net financing inflows. Cash and cash equivalents ended at $365,000, while unused finance facilities stood at $447,000, producing an estimated 1.51 quarters of funding at the reported operating cash rate. The bank balance includes $214,000 held in Egypt that is restricted.

The company answered “yes” to the Appendix 4C questions on maintaining its current cash outflow, raising further funds and continuing operations. Its stated basis includes future capital raisings, progress on the TBS contract and commercialisation projects. That makes financing execution a near-term requirement rather than a distant balance-sheet issue.

Egyptian investment review awaits records

Papyrus has also started a review of its Egyptian investment amid current losses, with MENA Associates working alongside AMERELLER to assess the arrangements and possible options. The company said a document request has been issued to local management, but the requested information had not been received by the report date. The Appendix 4C excludes Papyrus Egypt’s financial information because the investment was written down to zero at the end of FY25, although Papyrus’s shareholding interests remain unchanged.

The immediate test is therefore twofold: whether TBS accepts the improved board samples, and whether Papyrus can fund the business long enough to reach that decision and any subsequent production ramp-up. Neither milestone has yet been secured.